Use of Infliximab,an Anti-Tumor Necrosis Alpha Antibody,for Inflammatory Dermatoses

Abstract

French

Background:

Infliximab is a monoclonal antibody against tumor necrosis factor alpha currently approved by the U.S. FDA for the treatment of Crohn's disease and rheumatoid arthritis. Recently, a controlled trial reported its effectiveness for psoriasis.

Objective:

The object of our study was to evaluate the efficacy and safety of infliximab for inflammatory or autoimmune cutaneous disorders.

Methods:

A retrospective chart review was performed for patients who received infliximab at the University of Miami, Cedars Medical Center.

Results:

Patients with various disease, including panniculitis, pityriasis rubra pilaris, eosinophilic fasciitis, discoid lupus erythematosus, and necrobiosis lipoidica diabeticorum, received infliximab infusion at a dose of 5 mg/kg. All patients had refractory disease or adverse effects to previous therapy, which included cyclosporine, systemic steroids, azathioprin, clofazimine, mycophenolate mofetil, acitretin, UVB, and thalidomide. Six out of the seven patients improved after treatment.

Conclusions:

Infliximab was well tolerated in most patients and the majority benefited from the use of infliximab.

Get full access to this article

View all access options for this article.

References

Braun

Xiang

Brandt

. Treatment of spondyloarthropathies with antibodies against tumor necrosis factor alpha: First clinical and laboratory experiences. Ann Rheum Dis 2000; 59(Suppl I):i85–i89.

Van den Bosch

Kruithof

De Vos

. Crohn's disease associated with spondyloarthropathy: Effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356 (9244): 1821–1822.

Schwartz

Looney

O'Keefe

. Anti-TNF alpha therapy as a clinical intervention for periprosthetic osteolysis. Arthritis Res 2000;23:165–168.

Kobbe

Schneider

Rohr

. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse anti-TNFalpha antibody. Bone Marrow Transplant 2001; 281:47–49.

Couriel

Hicks

Giralt

. Role of tumor necrosis alpha inhibition with infliximab in cancer therapy and hematopoietic stem cell transplantation. Curr Opin Oncol 2000; 126:582–587.

Chaudhari

Romano

Mulcahy

. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomized trial. Lancet 2001; 357:1842–1847.

Ogilvie

ALJ

Antoni

Dechant

. Treatment of psoriatic arthritis with antitumor necrosis factor alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001; 144:587–589.

Hughes

Jackson

Callen

. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000; 284:1546–1548.

Botros

Pickover

Das

. Image of the month: Pyoderma gangrenosum caused by ulcerative colitis. Gastroenterology 2000; 118:654–809.

10.

Goossens

Verburg

Breedveld

. Remission of Behcôet's syndrome with tumor necrosis alpha blocking therapy. Ann Rheum Dis 2001; 60(6):637.

11.

Robertson

Hickling

. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab. Rheumatology 2001; 40:473–474.

12.

Baughman

Lower

. Infliximab for refractory sarcoidosis. Sarcoidosis Vase Diffuse Lung Dis 2001; 181:70.

13.

Geyer

Anhalt

Nossari

. Effectiveness of infliximab in the treatment of refractory perineal cutaneous Crohn disease. Arch Dermatol 2000; 136:459–460.

14.

Mahadevan

Sandborn

. Infliximab for the treatment of orofacial Crohn's disease. Inflamm Bowel Dis 2001; 71:38–42.

15.

Sullivan

Welsh

Kerdel

. Infliximab for hidradenitis supprativa, submitted for publication.

16.

Geren

Kerdel

Falabella

. Infliximab: A treatment option for ulcerative pyoderma gangrenosum. Wounds 2003; in press.

17.

Keane

Gershon

Wise

. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345(15):1098–1104.

18.

Martinez

Nunez O

Noiseux

Ripoll C

Martin

Carneros JA

. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment. Am J Gastroenterol 2001; 96(5): 1665–1666.

19.

Conaghan

Sommer

McGonagle

. The relationship between pityriasis rubra pilaris and inflammatory arthritis: Case report and response of the arthritis to anti-tumor necrosis alpha immunotherapy. Arthritis Rheum 1999; 42 (9): 1998–2001.

20.

Markham

Lamb

. Infliximab: A review of its use in the management of rheumatoid arthritis. Drugs 2000; 59:1342–1359.

21.

Maini

St. Clair

Breedveld

. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial. Lancet 1999; 354:1932–1939.

22.

Anonvmouslnfliximab, Mosby's GenRx, 11th ed.C.V. Mosby, Inc.,St. Louis, MO 2001.

23.

Papadakis

Targan

. Tumor necrosis factor: Biology and therapeutic inhibitors. Gastroenterology 2000; 119:1148–1157.

24.

Dinarello

. Proinflammatory cytokines. Chest 2000; 1182:503–509.

25.

Schaible

. Long term safety of infliximab. Can J Gastroenterol 2000; 14(Suppl C):29C–52C.

26.

Charles

Smeenk

De Jong

. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to TNFalpha: Findings in label and randomized placebo controlled trials. Arthritis Rheum 2000; 43(11):2383–2390.

27.

Watts

. Musculoskeletal and systemic reactions to biological therapeutic agents. Cur Opin Rheum 2000; 12:49–52.

28.

Bell

Kamm

. Antibodies to tumor necrosis factor alpha as treatment for Crohn's disease. Lancet 2000; 355:858–860.

29.

Mann

. Inflammatory mediators and the failing heart: Past, present, and the foreseeable future. Circ Res 2002; 91(11):988–998.

30.

Furst

Breedveld

Burmester

. Updated consensus statement on tumor necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000). Ann Rheum Dis 2000; 59 Suppl 1:i1–i2.

31.

Young

Vosper

. Elevated expression of the genes encoding TNF-alpha and thromboxane synthase in leucocytes from patients with systemic sclerosis. Rheumatology 2002; 41(8):869–875.

32.

Hasegawa

Fujimoto

Kikuchi

. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: Association with pulmonary fibrosis. J Rheumatol 1997; 24(4):663–665.

33.

Espana

Sanchez-Yus

Sema

. Chronic balanitis with palisading granuloma: An atypical genital localization of necrobiosis lipoidica responsive to pentoxifylline. Dermatology 1994; 188(3):222–225.

34.

Noz

Korstanje

Vermeer

. Ulcerating necrobiosis lipoidica effectively treated with pentoxifylline. Clin Exp Dermatol 1994; 18(1):78–79.

35.

Ordi–Ros

Cortes

Cucurull

. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol 2000; 27(6):1429–1433.

36.

Werth

Zhang

Dortzbach

. Association of a promoter polymorphism of tumor necrosis factor-alpha with subacute cutaneous lupus erythematosus and distinct photo-regulation of transcription. J Invest Dermatol 2000; 115(4):726–730.

37.

Fautrel

Foltz

Frances

. Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent. Arthritis Rheum 2002; 46(5): 1408–1409.